Description(s):
The FMS-like tyrosine kinase 3 (FLT3) also known as cluster of differentiation antigen 135 (CD135) or fetal liver kinase-2 (Flk2) is a class III receptor tyrosine kinase (RTK) that plays a key role in controlling survival, proliferation, and differentiation of hematopoietic cells and it widely express in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Mutations in FLT3 (both internal tandem duplications (ITD) and point mutations) are among the most common somatic mutations in AML patients and are associated with poor prognosis and outcome in those patients.
Due to the expression of FLT3 in the B cell lineage, as well as dendritic cells, it has an important role in regulating immunity. Therefore, targeted inhibition of FLT3 has been suggested for the treatment of both autoimmune disease and cancer.
Additionally, FLT3 is an important cell surface marker that can be used to identify certain types of hematopoietic (blood) progenitors in the bone marrow. We have generated Ba/F3 cell line that stably expresses FLT3 wild type. This cell line is mycoplasma free and expression of FLT3 has been validated by western blot.
Application
The cell line can be used;
- for screening antibodies or compounds against FLT3
- for studying cancer-related pathways in AML
- for studying immune system-related pathways
- as a cellular marker for separation of hematopoietic cells
Data
FLT3 wt Ba/F3 Cell Line treated with Gilteritinib. FLT3 wt Ba/F3 Cell line was treated with varying concentrations of Gilteritinib over a period of 3 days. Our Cell Viability Cytotoxicity (CVC) reagent (Cat# CVC001) was then used to check the viability of the cells.. The data was graphed and the IC50 was determined to be at a concentration of 14.03377 nM.
